After the doctor reviews the patient in a consultation, it will determine if the patient is suitable to be prescribed the medication
The focus is on simplifying access to treatment while keeping costs predictable through a flat monthly pricing structure
In addition, IHC for VEGF-A (Proteintech, Chicago, IL, USA) and CD34 (Proteintech, Chicago, IL, USA) were performed using the automated IHC system (Hoffman La-Roche Ltd., Basel, Switzerland)
Key findings include: Unprecedented HbA1c reductions ranging from 1.9% to 2.6% across different trials and populations SURPASS-1 (monotherapy): Up to 92% of participants achieved HbA1c less than 7%, with 52% reaching normoglycemia (HbA1c less than 5.7%) SURPASS-2 (versus semaglutide 1 mg): GLP2 demonstrated superior HbA1c and weight reduction at all doses compared to the leading GLP-1 receptor agonist SURPASS-3 (versus insulin degludec): Superior glycemic control when added to metformin with or without SGLT2 inhibitors SURPASS-4 (versus insulin glargine): Improved outcomes in patients with elevated cardiovascular risk Across all SURPASS trials, GLP2 showed consistent efficacy with low rates of clinically significant hypoglycemia (blood glucose less than 54 mg/dL)
